Su	ubstitute for form 1449A/PTO			COMPLETE IF KNOWN		
I	NFORMATION :	DIS	CLOSURE	Application Number	10/556,932	
6	TATEMENT BY	A TO	DI ICANIT	Filing Date	November 16, 2005	
3	IAIEMENI BY	AP	PLICANI	First Named Inventor	M. Moriya et al.	
	_			Group Art Unit	<u>1</u> 0556932 - GAU: 1624	
	(use as many sheets as necessary)			Examiner Name		
Sheet	1	of	2	Attorney Docket Number	BY0025P	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code		Date of Publication of Cited Document MM-DD-YYYY	
	•					

	FOREIGN PATENT DOCUMENTS							
	G:4-	Foreign Patent Document				Date of Publication of		
Examiner Initials*	Cite No.	Office Number		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY		
/DR/		WO 00/64877			Neurogen Corporation	11/02/2000		
XXXXX		w	O 02/02744		Synaptic Pharmaceutical Corporation	01/10/2002		
9000000		W	O 01/21577		Takeda Chemical Industries, Ltd.	03/29/2001		
999		W	O 99/48492		Japan Tobacco Inc.	09/03/1999		
830000		W	O 03/045313		Merck & Co., Inc.	06/05/2003		
00000		EP	1 285 651		Takeda Chemical Industries, Ltd.	02/26/2003		
IV		W	O 95/32967		SmithKline Beecham PLC	12/07/1995		
, v								

Examiner Signature /Deepak Rao/ Deepak Rao

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Substitute for form 1449B/PTO		COMPLETE IF KNOWN			
	NFORMATION	DIS	CLOSURE	Application Number	10/556,932	
	TO A TOTAL MEDIATOR TO S.	7 A D	DIICANT	Filing Date	November 16, 2005	
3	STATEMENT BY APPLICANT			First Named Inventor	M. Moriya et al.	
				Group Art Unit	_ 10556932 - GAU: 1624	
	(use as many sheets as necessary)			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	BY0025P	

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
/DR/	AA	Kowalski et al., Exp. Opin. Investig. Drugs, Vol. 13 (2004), pp. 1113-1122, "Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity"				
/DR/	AB	Clark et al., J. Med. Chem., Vol. 47 (2004), pp. 3962-3971, "A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor"				
/DR/	AC	Arienzo et al., Bioorg. & Medicinal Chem. Letters, Vol. 14 (2004), pp. 4099-4102, Structure-activity relationshps of a novel series of melanin-concentrating hormone (MCH) receptor antagonists"				
/DR/	AD	Kato et al., Chem. Abstracts, 134:266103, "Preparation of N-tetrahydronapththalenyl carboxamides as melanin concentrating hormone antagonists", 2001.				
/DR/	AE	Antelman et al., Chem. Abstracts, 91:68543, "The importance of stress in assessing the effects of anorectic drugs", 1979.				
/DR/	AF	Mueller et al., Chem. Abstracts 138:4532, "Preparation of quinolines as ligands for the neuropeptide Y receptor useful against arthritis, cardiovascular diseases, diabetes, renal failure, eating disordes and obesity" 2002				
	,					
·						

			00/00/0000
Examiner	I /Deepak Rao/	Date	06/22/2008
Signature	/ D d opart ride,	Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.